MedTrace Logo

Safety and Efficacy of LPE in Clearing DSA in Patients Who Received Allo-HSCT

NCT06177561 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2023-12-20

No results posted yet for this study

Summary

The aim of this study is to prospectively explore the effectiveness and safety of LPE in clearing DSA, and to investigate the clinical efficacy of a combination therapy with LPE in patients undergoing genetic hematopoietic stem cell transplantation.

Conditions

Interventions

PROCEDURE

Lymphoplasma exchange

The LPE treatment regimen is: LPE\*2 times (20-30ml/kg, treatment interval of 2 days);CD20 monoclonal antibody 375mg/m2\*2 times, gamma globulin 0.4g/kg/d\*5d.

Sponsors & Collaborators

  • Ruijin Hospital

    lead OTHER

Principal Investigators

  • Xiaoxia Hu, Dr · Ruijin Hospital

  • Xuefeng Wang, Dr · Ruijin Hospital

  • Zilu Zhang, Dr · Ruijin Hospital

  • Xiaohong Cai, Dr · Ruijin Hospital

  • Xi Wu, Dr · Ruijin Hospital

  • Jialu Zhao, bachelor · Ruijin Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-09
Primary Completion
2024-11-08
Completion
2025-11-08

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06177561 on ClinicalTrials.gov